查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1878861

鼻腔給藥市場－全球產業規模、佔有率、趨勢、機會和預測，依藥物類型、劑型、治療應用、最終用戶、地區和競爭格局分類，2020-2030年預測

Nasal Drug Delivery Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Dosage Form, By Therapeutic Application, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球鼻腔給藥市場規模為596.7億美元，預計到2030年將以7.66%的複合年成長率成長至929.1億美元。鼻腔給藥是指利用鼻腔豐富的血管分佈和藥物直達大腦的潛力，將治療藥物直接輸送到鼻腔進行局部或全身吸收。推動此市場成長的主要因素包括：患者對非侵入性給藥方式的偏好日益增強、起效迅速以及避免肝臟首過代謝，這些因素共同提高了藥物的生物利用度和治療效果。慢性呼吸系統疾病盛行率的上升以及對便捷的自我給藥方式的需求也顯著促進了市場擴張。

市場概覽
預測期 2026-2030
2024年市場規模 596.7億美元
2030年市場規模 929.1億美元
2025-2030年複合年成長率 7.66%
成長最快的細分市場 皮質類固醇
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：客戶之聲

第5章：全球鼻腔給藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類型分類（抗組織胺、皮質類固醇、麻醉藥、抗生素、止痛藥、其他）
    • 依劑型（噴霧劑、滴劑、粉末、凝膠劑和軟膏劑）分類
    • 依治療應用（氣喘、慢性阻塞性肺病（COPD）、鼻炎、囊性纖維化、鼻塞）
    • 按最終使用者（家庭護理機構、醫院、診所）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美鼻腔給藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲鼻腔給藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區鼻腔給藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲鼻腔給藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲鼻腔給藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球鼻腔給藥市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • GlaxoSmithKline Plc
  • Pfizer, Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Becton Dickson & Company
  • Cadila Pharmaceuticals Ltd.
  • 3M Company
  • Johnson & Johnson
  • Sanofi SA
  • Merck & Co., Inc.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 5174

The Global Nasal Drug Delivery Market, valued at USD 59.67 Billion in 2024, is projected to experience a CAGR of 7.66% to reach USD 92.91 Billion by 2030. Nasal drug delivery involves administering therapeutic agents directly to the nasal cavity for local or systemic absorption, utilizing its rich vascularization and the potential for direct brain access. Main drivers supporting this market's growth include increasing patient preference for non-invasive drug administration, the rapid onset of action, and the avoidance of hepatic first-pass metabolism, which collectively enhance drug bioavailability and therapeutic efficacy. The rising prevalence of chronic respiratory conditions and the demand for convenient self-administration methods also notably contribute to market expansion.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 59.67 Billion
Market Size 2030USD 92.91 Billion
CAGR 2025-20307.66%
Fastest Growing SegmentCorticosteroids
Largest MarketNorth America

Key Market Drivers

The increasing patient preference for non-invasive drug administration significantly influences the growth trajectory of the global nasal drug delivery market. Patients often favor routes that minimize discomfort and inconvenience, promoting better adherence to treatment regimens, particularly for long-term therapies or conditions requiring frequent dosing. This preference is evident in a broad range of therapeutic areas, driving pharmaceutical companies to develop and optimize nasal formulations for conditions traditionally managed by injectables.

Key Market Challenges

The inherent limitation of drug permeability across the nasal mucosal barrier presents a significant constraint on the growth of the Global Nasal Drug Delivery Market. This physiological hurdle complicates the formulation and effective systemic or even local delivery of large molecule pharmaceuticals, such as peptides, proteins, and antibodies. These larger therapeutic agents often struggle to traverse the tightly regulated nasal lining, hindering their optimal absorption into the bloodstream or direct access to the brain.

Key Market Trends

Nose-to-brain delivery for central nervous system (CNS) therapeutics represents an emerging and highly promising approach that exploits the unique anatomical pathways of the nasal cavity to bypass the blood-brain barrier and deliver drugs directly to the brain. This targeted route enables higher therapeutic concentrations in the CNS while reducing systemic exposure and minimizing associated side effects. As a result, it offers significant potential for the treatment of complex neurological and psychiatric disorders, including Alzheimer's and Parkinson's diseases, where conventional delivery methods often face limited efficacy.

Key Market Players

  • GlaxoSmithKline Plc
  • Pfizer, Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Becton Dickson & Company
  • Cadila Pharmaceuticals Ltd.
  • 3M Company
  • Johnson & Johnson
  • Sanofi S.A.
  • Merck & Co., Inc.

Report Scope:

In this report, the Global Nasal Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nasal Drug Delivery Market, By Drug Type:

  • Antihistamines
  • Corticosteroids
  • Anesthetics
  • Antibiotics
  • Pain Relief Drugs
  • Others

Nasal Drug Delivery Market, By Dosage Form:

  • Sprays
  • Drops
  • Powder
  • Gels & Ointments

Nasal Drug Delivery Market, By Therapeutic Application:

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Rhinitis
  • Cystic Fibrosis
  • Nasal Congestion

Nasal Drug Delivery Market, By End User:

  • Home Care Settings
  • Hospitals
  • Clinics

Nasal Drug Delivery Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nasal Drug Delivery Market.

Available Customizations:

Global Nasal Drug Delivery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nasal Drug Delivery Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Antihistamines, Corticosteroids, Anesthetics, Antibiotics, Pain Relief Drugs, Others)
    • 5.2.2. By Dosage Form (Sprays, Drops, Powder, Gels & Ointments)
    • 5.2.3. By Therapeutic Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Rhinitis, Cystic Fibrosis, Nasal Congestion)
    • 5.2.4. By End User (Home Care Settings, Hospitals, Clinics)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Nasal Drug Delivery Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Dosage Form
    • 6.2.3. By Therapeutic Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Nasal Drug Delivery Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Dosage Form
        • 6.3.1.2.3. By Therapeutic Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Nasal Drug Delivery Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Dosage Form
        • 6.3.2.2.3. By Therapeutic Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Nasal Drug Delivery Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Dosage Form
        • 6.3.3.2.3. By Therapeutic Application
        • 6.3.3.2.4. By End User

7. Europe Nasal Drug Delivery Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Dosage Form
    • 7.2.3. By Therapeutic Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Nasal Drug Delivery Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Dosage Form
        • 7.3.1.2.3. By Therapeutic Application
        • 7.3.1.2.4. By End User
    • 7.3.2. France Nasal Drug Delivery Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Dosage Form
        • 7.3.2.2.3. By Therapeutic Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Nasal Drug Delivery Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Dosage Form
        • 7.3.3.2.3. By Therapeutic Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Nasal Drug Delivery Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Dosage Form
        • 7.3.4.2.3. By Therapeutic Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Nasal Drug Delivery Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Dosage Form
        • 7.3.5.2.3. By Therapeutic Application
        • 7.3.5.2.4. By End User

8. Asia Pacific Nasal Drug Delivery Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Dosage Form
    • 8.2.3. By Therapeutic Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Nasal Drug Delivery Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Dosage Form
        • 8.3.1.2.3. By Therapeutic Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Nasal Drug Delivery Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Dosage Form
        • 8.3.2.2.3. By Therapeutic Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Nasal Drug Delivery Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Dosage Form
        • 8.3.3.2.3. By Therapeutic Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Nasal Drug Delivery Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Dosage Form
        • 8.3.4.2.3. By Therapeutic Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Nasal Drug Delivery Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Dosage Form
        • 8.3.5.2.3. By Therapeutic Application
        • 8.3.5.2.4. By End User

9. Middle East & Africa Nasal Drug Delivery Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Dosage Form
    • 9.2.3. By Therapeutic Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Nasal Drug Delivery Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Dosage Form
        • 9.3.1.2.3. By Therapeutic Application
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Nasal Drug Delivery Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Dosage Form
        • 9.3.2.2.3. By Therapeutic Application
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Nasal Drug Delivery Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Dosage Form
        • 9.3.3.2.3. By Therapeutic Application
        • 9.3.3.2.4. By End User

10. South America Nasal Drug Delivery Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Dosage Form
    • 10.2.3. By Therapeutic Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Nasal Drug Delivery Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Dosage Form
        • 10.3.1.2.3. By Therapeutic Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Nasal Drug Delivery Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Dosage Form
        • 10.3.2.2.3. By Therapeutic Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Nasal Drug Delivery Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Dosage Form
        • 10.3.3.2.3. By Therapeutic Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Nasal Drug Delivery Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GlaxoSmithKline Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer, Inc.
  • 15.3. AstraZeneca PLC
  • 15.4. Novartis AG
  • 15.5. Becton Dickson & Company
  • 15.6. Cadila Pharmaceuticals Ltd.
  • 15.7. 3M Company
  • 15.8. Johnson & Johnson
  • 15.9. Sanofi S.A.
  • 15.10. Merck & Co., Inc.

16. Strategic Recommendations

17. About Us & Disclaimer